Effects of Low-dose Naltrexone in Combination With a Range of Smoked Marijuana
NCT ID: NCT00743145
Last Updated: 2018-09-14
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
23 participants
INTERVENTIONAL
2008-05-31
2009-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of a Range of Naltrexone Doses in Combination With Smoked Marijuana
NCT00403117
Opioid and Cannabinoid Pharmacokinetic Interactions
NCT00308555
Evaluation of Medical Cannabis and Prescription Opioid Taper Support for Reduction of Pain and Opioid Dose in Patients With Chronic Non-Cancer Pain
NCT04827992
Analgesic Efficacy of Smoked Cannabis
NCT00241579
Repeated Cannabis Administration on Experimental Pain and Abuse Liability
NCT04576507
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo naltrexone + Inactive marijuana
Placebo naltrexone capsules (0mg), inactive marijuana (0% THC). Each study participant underwent 8 conditions in a randomized order.
Inactive Marijuana (0% THC)
Marijuana cigarette containing 0% THC
Placebo naltrexone
Naltrexone (0mg)
Placebo naltrexone + Active marijuana (5.5% THC)
Placebo naltrexone capsules (0mg), active marijuana (5.5% THC). Each study participant underwent 8 conditions in a randomized order.
Active Marijuana (5.5% THC)
Marijuana cigarette containing 5.5% THC
Placebo naltrexone
Naltrexone (0mg)
Placebo naltrexone + Active marijuana (6.2% THC)
Placebo naltrexone capsules (0mg), active marijuana (6.2% THC). Each study participant underwent 8 conditions in a randomized order.
Active Marijuana (6.2% THC)
Marijuana cigarette containing 6.2% THC
Placebo naltrexone
Naltrexone (0mg)
Naltrexone + Active marijuana (5.5% THC)
Naltrexone capsules (12mg), active marijuana (5.5% THC). Each study participant underwent 8 conditions in a randomized order.
Active Marijuana (5.5% THC)
Marijuana cigarette containing 5.5% THC
Naltrexone
Naltrexone (12mg/70kg)
Naltrexone + Active marijuana (6.2% THC)
Naltrexone capsules (0mg), active marijuana (6.2% THC). Each study participant underwent 8 conditions in a randomized order.
Active Marijuana (6.2% THC)
Marijuana cigarette containing 6.2% THC
Naltrexone
Naltrexone (12mg/70kg)
Naltrexone + Inactive marijuana
Naltrexone capsules (12mg), inactive marijuana (0% THC). Each study participant underwent 8 conditions in a randomized order.
Inactive Marijuana (0% THC)
Marijuana cigarette containing 0% THC
Naltrexone
Naltrexone (12mg/70kg)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Inactive Marijuana (0% THC)
Marijuana cigarette containing 0% THC
Active Marijuana (5.5% THC)
Marijuana cigarette containing 5.5% THC
Active Marijuana (6.2% THC)
Marijuana cigarette containing 6.2% THC
Naltrexone
Naltrexone (12mg/70kg)
Placebo naltrexone
Naltrexone (0mg)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Able to perform study procedures
* Women practicing an effective form of birth control
Exclusion Criteria
* Presence of significant medical illness (e.g., diabetes, cardiovascular disease,hypertension, hepatitis, clinically significant laboratory abnormalities, LFTs \> 3x upper limit of normal, blood pressure \> 140/90
21 Years
45 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Research Foundation for Mental Hygiene, Inc.
OTHER
National Institute on Drug Abuse (NIDA)
NIH
New York State Psychiatric Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Margaret Haney
Clinical Psychaitrist
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Margaret Haney, Ph.D.
Role: PRINCIPAL_INVESTIGATOR
New York State Psychiatric Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
New York State Psychiatric Institute
New York, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DA19239
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
IRB# 5693
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.